Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Salut
I´m Back...Position 22,2 $
à bientôt
France
Gap ? 19--20 $ ?
Salut
I am finished with ORMP
Hi...Muddi
à bientôt
France
Salut
Patente News
JERUSALEM, January 2, 2014 /PRNewswire/ --
?
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has received Notices of Allowance from the Israel and Australian Patent Offices. The patent entitled, "Methods and Compositions for Oral Administrations of Proteins" covers a core concept of the company's technology for the oral delivery of drugs and vaccines currently delivered via injection. The allowance in Israel marks the second from the Israel Patent Office in the past 30 days. Additionally, this is Oramed's second Australian patent allowance, following the grant of a different patent in May 2012. The patent has also been approved in Japan, China, Russia, and New Zealand.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD[TM]) technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), with trials underway. Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company's corporate and R&D headquarters are based in Jerusalem.
For more information, the content of which is not part of this press release, please visit http://www.oramed.com
Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials or revolutionizing the treatment of diabetes with our products. These forward-looking statements and their implications are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.
Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Office: +972-2-566-0001
Email: aviva@oramed.com
SOURCE Oramed Pharmaceuticals Inc.
Copyright 2014 PR Newswire
à bientôt
France
Salut
reaaalist (German User )mailing Australia & Israel Patente
Have a nice r
à bientôt
France
Hello Germany (stuttgard)
Have a nice day
France
Salut
Thx Oramed....I love it...
Best Regards
Occitanie
What.....Waiting for...
For reaaalist in Germany
à bientôt
France
Salut
Please Don´t pusching...
Arrêtez de faire monter la Mayonnaise...
Monsieur Lehner est un escroc...
Eric Lehner ist a Clown....and smiling with my Money
à bientôt
France
Salut
I m a German Scharesholders...
I´m very tired for waiting since 4 year..
I say only..."Schame on you Mr Lehner "
à bientôt
France
Salut
Sorry ,I try it again
[url][/url][tag]http://www.dailymotion.com/video/xqbtw6_oramed-insulin-pill-development-drug-trials_news[/tag]
CEO said FDA of the Ende this year...
I think Oramed ist On the Best way....
à bientôt
France
Salut
Video on Blomberg
http://www.dailymotion.com/video/xqbtw6_oramed-insulin-pill-development-drug-trials_news" rel="nofollow" target="_blank" >http://www.dailymotion.com/video/xqbtw6_oramed-insulin-pill-development-drug-trials_news
Moving up...Soon...
Hello reaaalist
à bientôt
France
Salut
DIE NOTIERUNG FOLGENDER AKTIEN WIRD MIT ABLAUF DES 17.05.2011 EINGESTELLT:
THE FOLLOWING SHARES WILL BE DELISTED AFTER POST TRADING ON MAY 17, 2011:
ISIN SHORT CODE LONGNAME
CA7030123029 P3M Patch International Inc.
CA7294151096 L9F Plutonic Power Corp.
GB0032875873 GMP GMA Resources PLC
GB00B55WYH03 ASKA Global Property Support Network PLC
SG1Y63947648 PAI Passion Holdings Ltd.
US0373551045 EM1A Anything Technologies Media Inc.
US14044M2098 0CR Capital Resources Alliance Inc. [new]
US29426L1089 POF Epicor Software Corp.
US3611571007 3FN Future Now Group Inc.
US4447501036 XSM2 Hull Energy Inc.
US4577331030 IR1 Inspire Pharmaceuticals Inc.
US4598312027 4FDN International Luxury Products Inc.
US5574481074 M1O Madison Exploration Inc.
US5754241066 0MP MASS Petroleum Inc.
US6386841000 PTDA Nationwide Utilities Corp.
US7310361099 62O Polar Wireless Corp.
US9750121058 WMU Winning Brands Corp.
A´bientôt
France
Salut
Frankfurt (Germany)--->Delisted ?
Mrs Lehner...you are 1 Bandit
France
Hi juda
Sorry...i ´m not in Time
But i Think R/S ist now....inkluding on Price-->
0,25$---0,29 $
I hope...
Many good News----Big Sell (370 000 Schares) and Schares Price ist not moving down...
Just what i mean....without Garantie.
à bientôt
France
Sorry but...
Serbien
Ghana...Soon Vatikan: 0,44 km² - 932 Einwohner..
Big Deal....
à bientôt
France
Salut
Serbia....It´s a Jok...No money.
Why not...Germany...
à bientôt
France
Salut
But no Buy...No Sell
Germany ist Waiting..for USA ...Tomorrow...
à bientôt
France
Salut
Yes....Europa...and Frankfurt am Main....
21.02.11 09:09:28 Uhr
0,003 EUR
+50,00% [+0,00]
á bientôt
France
Salut
I´m not a big player...i have only 488 888 Schares buying bei
Frankfurt (Germany) to 0,006€ (0,0082 $ )
But i hope good News coming soon with Next Interwiew on February 1 st...
I hope...I hope
à bientôt
OC
Salut
I´m very surprise...nobody here
But Oramed make a big steep every times
Soon--->FDA--->Nasdasq....
à bientôt
OC
Salut
All what i´m reading..here...it´s only Eric Demontage
I ´m since 2,5 years in...I´m dissapointed about the Schres price...but...i hope..Big News coming soon...
And...I Think Eric do a great Job..with a Great Produit
à bientôt
France
Salut
Wo are people
Oramed have a great potential
I think...2011...FDA..Nasdaq....
à bientôt
France
Salut
Great Blogs.....But now....we need a Great News/PR...
Blogs and Blogs...more Blogs...People doesn´t known...
Here i ´m....
à bientôt
France
Salut
I post it ins German Board
In the USA thread are ami's crossly on Eric---> Dillution
Either he needs to finance the money around the Production ?----> then would be positive
or around his salary assure .... would be abzockern....
Delightfully ... I do not know at the moment where the trip goes....
Hope for 1 positive news around us weider trust to profits....
Am my thing ... every day uncertainly .... and my EK-> 0,007 € hurts
à bientôt
France
Salut....
i´m dissapointed...but i don´t think so about Eric.
à bientôt
French kiss
Greeting
I am New At I-Hub...
I wait for more than one and a half year... That this firm finally carries the Fruits of its Efforts...
But it's a pity to note that the price of Schares is too much low.... I Hope that President of this society will surprise us with a good News... Because I end up losing patience and if I sell it is going to hurt..
I am Sorry to Translate my French to Englisch with a Programm... I am stockholder in Germany.... Frankfurt am Main....
by the way we read your writings every day...
Attention...
In Germany this society is not much known... I think that Efforts of the president a feeling should concentrate on Countries European who ècologique is strong by Example... Germany..
The suéde... The France... The Denmark... It is definitivly more lucrativ than to content itself to The amerique who the rate of pollution by People is one furthermore biggest in the world..
If they sell one Produced Biodégrade a market European is for it much more profitable
One Question which interrese me:
Why this Firm was not profitable of had a great time polluting to americaines Coasts.
A lot of Question?
Á soon
OC